Living Cell Technologies Limited
LVCLY · OTC
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.28 | 0.25 | 0.24 | -0.10 |
| FCF Yield | -13.62% | -14.04% | -53.11% | -20.12% |
| EV / EBITDA | -3.67 | -7.92 | 0.26 | -4.26 |
| Quality | ||||
| ROIC | -73.01% | -56.60% | -48.59% | -126.85% |
| Gross Margin | 0.00% | 98.67% | 78.18% | 81.61% |
| Cash Conversion Ratio | 0.73 | 0.94 | 1.04 | 1.00 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -46.09% | 2.43% | 201.67% |
| Free Cash Flow Growth | 23.31% | 2.92% | -39.99% | 53.00% |
| Safety | ||||
| Net Debt / EBITDA | 1.41 | 3.24 | 2.91 | 1.17 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -119,861.83 | -19,827.39 | -302.24 |